No Data
Exscientia Outline Robot and AI Use in Drug Discovery Workflow
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom
Morgan Stanley Maintains Exscientia(EXAI.US) With Hold Rating, Maintains Target Price $5.7
The English silicon asia vets has reached a milestone in AI pharmaceuticals.
ISM001-055 demonstrates ideal safety and efficacy trends in Phase IIa, surpassing market and company expectations, bringing more imaginative prospects for the company.
Morgan Stanley Maintains Exscientia(EXAI.US) With Hold Rating, Cuts Target Price to $5.7
Exscientia Plc (EXAI): A Penny Stock That Will Make You a Millionaire